Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,280 active trials259 approved drugs3,813 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics465
Variants & evidence3813
Drugs427
Trials91351
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,399)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,976–4,000 of 4,399 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.
· Proc Natl Acad Sci U S A · 2005 · PMID 15705718 · validated civic_curation pubmed
Integrated molecular analysis of adult T cell leukemia/lymphoma.
· Nat Genet · 2015 · PMID 26437031 · validated civic_curation pubmed
PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.
· Blood · 2018 · PMID 29434033 · validated civic_curation pubmed
PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
· Cancer Discov · 2017 · PMID 28446439 · validated civic_curation pubmed
Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
· Cancer Biol Ther · 2016 · PMID 26650448 · validated civic_curation pubmed
p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3.
· Mol Cancer Ther · 2007 · PMID 17363498 · validated civic_curation pubmed
Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
· Clin Cancer Res · 2018 · PMID 30171048 · validated civic_curation pubmed

Showing 3,976–4,000 of 4,399 publications

← Previous
1
…
159
160
161
…
176
Next →

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.

· Nat Commun · 2019 · PMID 31399568 · validated civic_curation pubmed

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

· Nature · 2017 · PMID 28783719 · validated civic_curation pubmed

Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.

· Leuk Res · 2014 · PMID 24367893 · validated civic_curation pubmed

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.

· Clin Cancer Res · 2015 · PMID 26296355 · validated civic_curation pubmed

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.

· EBioMedicine · 2016 · PMID 26870817 · validated civic_curation pubmed

Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.

· Br J Cancer · 2010 · PMID 20147967 · validated civic_curation pubmed

Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.

· Mol Cancer Ther · 2018 · PMID 29237803 · validated civic_curation pubmed

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

· J Clin Invest · 2009 · PMID 19381019 · validated civic_curation pubmed

FGFR3S249C mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells.

· Exp Ther Med · 2019 · PMID 31316618 · validated civic_curation pubmed

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

· Oncogene · 2007 · PMID 17384684 · validated civic_curation pubmed

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

· Nat Commun · 2019 · PMID 31160589 · validated civic_curation pubmed

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

· Oncogene · 2009 · PMID 19749790 · validated civic_curation pubmed

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

· Blood · 2004 · PMID 15178581 · validated civic_curation pubmed

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.

· Blood · 2017 · PMID 27908881 · validated civic_curation pubmed

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.

· Oncotarget · 2017 · PMID 28002790 · validated civic_curation pubmed

Loss of Atrx sensitizes cells to DNA damaging agents through p53-mediated death pathways.

· PLoS One · 2012 · PMID 23284920 · validated civic_curation pubmed

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

· Cell · 2004 · PMID 15035987 · validated civic_curation pubmed

The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.

· Am J Cancer Res · 2016 · PMID 27904766 · validated civic_curation pubmed